Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …

Human cytomegalovirus (HCMV) reactivation is a major infectious cause of morbidity and
mortality after allogeneic hematopoietic stem cell transplantation (HSCT). HCMV is a …

Background Cytomegalovirus (CMV) infection remains a common complication after
allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the …

Cytomegalovirus (CMV) is a leading opportunistic infection in immune compromised
patients, including allogeneic hematopoietic stem cell (HSCT) or solid organ transplant …

Patients treated with allogeneic hematopoietic cell transplantation (HCT) are at risk of
cytomegalovirus (CMV) reactivation and disease, which results in increased morbidity and …

Human cytomegalovirus (HCMV) is responsible for life-threatening infections in
immunocompromised individuals and can cause serious congenital malformations …

The prevention and treatment of human cytomegalovirus (HCMV) infections is based on the
use of antiviral agents that currently target the viral DNA polymerase and that may cause …

Although invasive cytomegalovirus (CMV) disease is uncommon in the era of antiretroviral
therapy (ART), asymptomatic CMV coinfection is nearly ubiquitous in HIV infected …

Abstract Purpose of Review CMV DNA polymerase inhibitors such as ganciclovir and
foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient …

Human cytomegalovirus (HCMV) is one of the main causes of serious complications in
immunocompromised patients and after congenital infection. There are currently drugs …